Bicycle Therapeutics (BCYC) Cash from Operations (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Cash from Operations came in at 49606000.0 in Q2 2026, up 31.85% YoY from 37623974.28 in Q2 2025, and up 24.75% on a QoQ basis from 65925000.0 in Q1 2026.
Bicycle Therapeutics (BCYC) Cash from Operations (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Cash from Operations data on file, last reported at 49606000.0 in Q2 2026.
- Quarterly Cash from Operations rose 31.85% year-over-year to 49606000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 206050000.0 (up 1.12% YoY) and the FY2025 annual result came in at 249675000.0, down 51.57% from the prior year.
- Cash from Operations climbed to 49606000.0 in Q2 2026, from 65925000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 34096000.0 in Q2 2023 to a low of 86370000.0 in Q1 2025.
- A 5-year average of 37592722.22 and a median of 42229500.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 244.9% — and 2024, when it tumbled 3786.05%.
- Tracing BCYC's Cash from Operations over 5 years: stood at 30309000.0 in 2022, then slumped by 56.02% to 47288000.0 in 2023, then surged by 80.13% to 9396000.0 in 2024, then slumped by 105.9% to 19346000.0 in 2025, then tumbled by 156.41% to 49606000.0 in 2026.
- The last three Cash from Operations figures came in at 49606000.0 (Q2 2026), 65925000.0 (Q1 2026), and 19346000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -49.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.61 Mn |
| Jun 30, 2026 | -49.61 Mn |
| Mar 31, 2026 | -65.93 Mn |
| Mar 31, 2026 | -65.93 Mn |
| Dec 31, 2025 | -19.35 Mn |
| Dec 31, 2025 | -19.35 Mn |
| Sep 30, 2025 | -71.17 Mn |
| Sep 30, 2025 | -71.17 Mn |
| Jun 30, 2025 | -72.79 Mn |
| Jun 30, 2025 | -72.79 Mn |
| Mar 31, 2025 | -86.37 Mn |
| Mar 31, 2025 | -86.37 Mn |
| Dec 31, 2024 | -9.40 Mn |
| Dec 31, 2024 | -9.40 Mn |
| Sep 30, 2024 | -39.83 Mn |
| Sep 30, 2024 | -39.83 Mn |
| Jun 30, 2024 | -44.63 Mn |
| Jun 30, 2024 | -44.63 Mn |
| Mar 31, 2024 | -70.87 Mn |
| Mar 31, 2024 | -70.87 Mn |